运作良好的国家监管机构(NRA)确保获得安全、有效,质量保证,和负担得起的医疗产品。然而,他们工作的好处往往看不见,也很难归因,从而使NRA被低估和资源不足,特别是在低收入和中等收入国家。本文提供了三个关键论据NRA和其他利益相关者可以用来倡导更大的投资监管系统加强医疗产品监管有效保障公众健康;有效的监管提高卫生系统的效率,通过增加获得负担得起的医疗产品,促进全民健康覆盖;强有力的监管加强了当地的药品制造,支持了药品贸易。NRA在卫生系统中的关键作用是无可争议的,然而,他们需要更好地提升自己的价值,以获得有效运作所需的资源。
Well-functioning national regulatory authorities (NRAs) ensure access to safe, effective, quality-assured, and affordable medical products. However, the benefits of their work are often unseen and difficult to attribute, thereby making NRAs undervalued and under-resourced, particularly in low- and middle-income countries. This paper offers three key arguments NRAs and other stakeholders can use to advocate for greater investment in regulatory systems strengthening-medical products regulation effectively safeguards public health; effective regulation improves health system\'s efficiency by increasing access to affordable medical products, contributing to universal health coverage; and robust regulation strengthens local pharmaceutical manufacturing and bolsters pharmaceutical trade. NRAs\' critical role in health systems is indisputable, yet they need to better promote their value to receive the requisite resources to function effectively.